New treatments for acute humoral rejection of kidney allografts

Expert Opinion on Investigational Drugs

Volumn 16, Issue 5, 2007, Pages 625-633

  Venetz, Jean Pierre ^c   Pascual, Manuel ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Geneva Lausanne Transplantation Network   (Switzerland)

^c NONE

Author keywords

Acute humoral rejection; Kidney allograft

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CD20 ANTIBODY; COMPLEMENT COMPONENT C4D; COMPLEMENT INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; EVEROLIMUS; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ANTIBODY PRODUCTION; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOMODULATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MENINX DISORDER; MONOTHERAPY; PLASMAPHERESIS; PNEUMONIA; REVIEW; SINGLE DRUG DOSE; SPLENECTOMY; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; B-LYMPHOCYTES; COMPLEMENT INACTIVATING AGENTS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 34248159578     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.5.625     Document Type: Review

References (65)

1. HALLORAN PF, WADGYMAR A, RITCHIE S et al.: The significance of anti-class I antibody response. I. Clinical and pathologic features of anti-class I mediated rejection. Transplantation (1990) 49:85-91.
2. HALLORAN PF, SCHLAUT J, SOLEZ K, SRINIVASA NS: The significance of anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation (1992) 53:550-555.
3. TRPKOV K, CAMPBELL T, PAZDERKA F et al.: Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation (1996) 61:1586-1592.
4. FEUCHT HE, FELBER E, GOKEL MJ et al.: Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin. Exp. Immunol. (1991) 86:464-470.
5. FEUCHT HE, SCHNEEBERGER H, HILLEBRAND et al.: Capillary deposition of C4d complement fragment and early graft loss. Kidney Int. (1993) 43:1333-1338.
6. PASCUAL M, SAIDMAN S, TOLKOFF-RUBIN N et al.: Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation (1998) 66:1460-1464.
7. COLLINS AB, SCHNEEBERGER EE, PASCUAL M et al.: Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. (1999) 10:2208-2214.
8. MONTGOMERY RA, HARDY MA, JORDAN SC et al.: Antibody Working Group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation (2004) 78:181-185.
9. CRESPO M, PASCUAL M, TOLKOFF-RUBIN N et al.: Acute humoral rejection in renal allograft recipients: Incidence, serology and clinical characteristics. Transplantation (2001) 71:652-658.
10. MAUIYYEDI S, CRESPO M, COLLINS AB et al.: Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology and pathologic classification. J. Am. Soc. Nephrol. (2002) 13:779-787.
11. BOHMIG GA, EXNER M, HABICHT A et al.: Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J. Am. Soc. Nephrol. (2002) 13:1091-1099.
12. MOLL S, PASCUAL M: Humoral rejection of organ allografts. Am. J. Transplant. (2005) 5:2611-2618.
13. HERZENBERG AM, GILL JS, DJURDJEV O, MAGIL AB: C4d deposition in acute rejection: an independent long-term prognostic factor. J. Am. Soc. Nephrol. (2002) 13:234-241.
14. KARPINSKI M, RUSH D, JEFFERY J et al.: Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J. Am. Soc. Nephrol. (2001) 12:2807-2814.
15. PERREY C, BRENCHLEY PE, JOHNSON RW, MARTIN S: An association between antibodies specific for endothelial cells and renal transplant failure. Transpl. Immunol. (1998) 6:101-106.
16. SUMITRAN-HOLGERSSON S, WILCZEK HE, HOLGERSSON J, SODERSTROM K: Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation (2002) 74:268-277.
17. BALDWIN WM, HALLORAN PF: Clinical syndromes associated with antibody in allografts. In: Kidney Transplant Rejection. Racusen LC, Solez K, Burdick JF (Eds), Marcel Decker, New York, USA (1998) 3:127-147.
18. HILL P, GAGLIARDINI E, RUGGENENTI P et al.: Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with campath-1H induction therapy. Nephrol. Dial. Transplant. (2005) 20:1741-1744.
19. WEINSTEIN D, BRAUN WE, COOK D et al.: Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft. Am. J. Transplant. (2005) 5:2576-2581.
20. BAID S, TOLKOFF-RUBIN N, SAIDMAN S et al.: Acute humoral rejection in hepatitis c-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant. (2003) 3:74-78.
21. TAKAHASHASHI K, SAITO K, TAKAHARA S et al.: JAPANESE ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION COMMITTEE: Excellent long-term outcome of ABO incompatible living donor kidney transplantation in Japan. Am. J. Transplant. (2004) 4:1089-1096.
22. WARREN DS, ZACHARY AA, SONNENDAY CJ et al.: Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am. J. Transplant. (2004) 4:561-568.
23. TYDEN G, KUMLIENJ G, GENBERG H et al.: ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am. J. Transplant. (2005) 5:145-148.
24. MONTGOMERY RA, ZACHARY AA: Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr. Transplant. (2004) 8:535-542.
25. MONTGOMERY RA, ZACHARY AA, RACUSEN LC et al.: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation (2000) 70:887-895.
26. JORDAN SC, QUARTEL AW, CZER LSC et al.: Postransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation (1988) 66:800-805.
27. ROCHA PN, BUTTERLY DW, GREENBERG A et al.: Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation (2003) 75:1490-1495.
28. WHITE NB, GREENSTEIN SM, CANTAFIO AW et al.: Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation (2004) 78:772-774.
29. BOHMIG GA, REGELE H, EXNER M et al.: C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J. Am. Soc. Nephrol. (2001) 12:2482-2489.
30. IBERNON M, GIL-VERNET S, CARRERA M et al.: Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant. Proc. (2005) 37:3743-3745.
31. BECKER YT, BECKER BN, PIRSCH JD et al.: Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant. (2004) 4:996-1001.
32. LEHRICH RW, ROCHA PN, REINSMOEN N et al.: Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum. Immunol. (2005) 66:350-358.
33. ABRAHAM KA, BROWN C, CONLON PJ et al.: Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J. Clin. Apheresis (2003) 18:103-110.
34. CASADEI DH, RIAL MC, RAIMONDI E et al.: Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo. Transplantation (1997) 63:1191-1192.
35. JORDAN SC, TYAN D, STABLEIN D et al.: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J. Am. Soc. Nephrol. (2004) 15:3256-3262.
36. SIVASAI KS, MOHANAKUMAR T, PHELAN D et al.: Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates. Clin. Exp. Immunol. (2000) 119:559-565.
37. STEGALL MD, GLOOR J, WINTERS JM et al.: A comparison of plasmapheresis versus high dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. (2006) 6:346-351.
38. SMITH KG, ISBEL NM, CATTON MG et al.: Suppression of the humoral immune response by mycophenolate mofetil. Nephrol. Dial. Transplant. (1998) 13:160-164.
39. BROEDERS N, WISSING KM, CRUSIAUX A et al.: Mycophenolate mofetil, together with cyclosporine A, prevents anti-OKT3 antibody response in kidney transplant recipients. J. Am. Soc. Nephrol. (1998) 9:1521-1525.
40. TERASAKI PI, OZAWA M: Predicting kidney graft failure by HLA antibodies: a prospective trial. Am. J. Transplant. (2004) 4:438-443.
41. VIEIRA CA, AGARWAL A, BOOK BK et al.: Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation (2004) 77:542-548.
42. TYDEN G, KUMLIEN G, FEHRMAN I: Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation (2003) 76:730-731.
43. GLOOR JM, DEGOEY SR, PINEDA AA et al.: Overcoming a positive crossmatch in living-donor kidney transplantation. Am. J. Transplant. (2003) 3:1017-1023.
44. ARANDA JM Jr, SCORNIK JC, NORMANN SJ et al.: Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation (2002) 73:907-910.
45. GARRETT HE, GROSHART K, DUVAL-SEARMAN D et al.: Treatment of acute humoral rejection with rituximab. Ann. Thorac. Surg. (2002) 74:1240-1242.
46. CRESPO M, AROSTEGUI JJ, ESFORZADO N et al.: A liver graft does not always protect a kidney graft from acute humoral rejection in combined transplantation. Transplant. Int. (2005) 18(Suppl. 1):44.
47. GENBERG H, HANSSON A, WERNERSON A, WENNBERG L, TYDEN G: Pharmacodynamics of rituximab in kidney allotransplantation. Am. J. Transplant. (2006) 6:2418-2428.
48. BEARDEN CM, AGARWAL A, BOOK BK et al.: Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am. J. Transplant. (2005) 5:50-57.
49. TOKUNAGA M, FUJII K, SAITO K et al.: Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (2005) 44:176-182.
50. JORDAN ML, NARAGHI R, SHAPIRO R et al.: Tacrolimus rescue therapy for renal allograft rejection - five-year experience. Transplantation (1997) 63:223-228.
51. LOSS GE Jr, GREWAL HP, SIEGEL CT et al.: Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. Transplant. Proc. (1998) 30:1249-1250.
52. JURCEVIC S, DUNN MJ, CRISP S et al.: A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation (1998) 65:1197-1202.
53. THERUVATH TP, SAIDMAN SL, MAUIYYEDI S et al.: Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation (2001) 72:77-83.
54. VINCENTI F: Protein therapies and antiproliferatives: a new paradigm in immunosuppression. Transplant. Rev. (2005) 19:179-185.
55. BENIAMINOVITZ A, ITESCU S, LIETZ K et al.: Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N. Engl. J. Med. (2000) 342:613-619.
56. KNECHTLE SJ, PIRSCH JD, FECHNER J Jr et al.: Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. (2003) 3:722-730.
57. SUNDERS RN, MATCALFE MS, NICHOLSAN ML: Rapamycin in transplantation: a review of the evidence. Kidney Int. (2001) 59:3-16.
58. AAGAARD-TILLERY KM, JELINEK DF: Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol. (1994) 156:493-507.
59. PESCOVITZ MD, BOOK BK, HENSON S et al.: The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am. J. Transplant. (2003) 3:497-500.
60. PASCUAL M, DUCHOSAL MA, STEIGER G et al.: Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J. Immunol. (1993) 151:1702-1711.
61. ZIMMERMAN JL, DELLINGER RP, STRAUBE RC et al.: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. (2000) 28:3149-3154.
62. PIERSON RN III, LOYD JE, GOODWIN A et al.: Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation (2002) 74:79-84.
63. HILLMEN P, YOUNG NS, SCHUBERT J et al.: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. (2006) 355:1233-1243.
64. GOLDENBERG DM: Epratuzumab in the therapy of ontological and immunological diseases. Expert Rev. Anticancer Ther. (2006) 6:1341-1353.
65. KEYSTONE E: B cell targeted therapies. Arthritis Res. Ther. (2005) 7(Suppl. 3):S13-S18.